{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:09:29Z","timestamp":1791641369251,"version":"4.3.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s40265-024-02089-2","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T06:03:23Z","timestamp":1726725803000},"page":"1319-1324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Golidocitinib: First Approval"],"prefix":"10.1007","volume":"84","author":[{"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"2089_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01560-7","author":"EWY Chang","year":"2024","unstructured":"Chang EWY, Tan YH, Chan JY. Novel clinical risk stratification and treatment strategies in relapsed\/refractory peripheral T-cell lymphoma. J Hematol Oncol. 2024. https:\/\/doi.org\/10.1186\/s13045-024-01560-7.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"2089_CR2","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","volume":"103","author":"M Bellei","year":"2018","unstructured":"Bellei M, Foss FM, Shustov AR, et al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica. 2018;103(7):1191\u20137.","journal-title":"Haematologica"},{"key":"2089_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00510-w","author":"H Huang","year":"2024","unstructured":"Huang H, Zhang W, Deng X, et al. Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting. Exp Hematol Oncol. 2024. https:\/\/doi.org\/10.1186\/s40164-024-00510-w.","journal-title":"Exp Hematol Oncol"},{"issue":"9","key":"2089_CR4","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1021\/acs.jmedchem.9b01392","volume":"63","author":"Q Su","year":"2020","unstructured":"Su Q, Banks E, Bebernitz G, et al. Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a potent and selective Janus kinase 1 inhibitor. J Med Chem. 2020;63(9):4517\u201327.","journal-title":"J Med Chem"},{"issue":"26","key":"2089_CR5","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1182\/blood.2021013379","volume":"138","author":"AJ Moskowitz","year":"2021","unstructured":"Moskowitz AJ, Ghione P, Jacobsen E, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas. Blood. 2021;138(26):2828\u201337.","journal-title":"Blood"},{"key":"2089_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071971","author":"AJ Brooks","year":"2020","unstructured":"Brooks AJ, Putoczki T. JAK-STAT signalling pathway in cancer. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12071971.","journal-title":"Cancers (Basel)."},{"issue":"11","key":"2089_CR7","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.annonc.2023.08.013","volume":"34","author":"Y Song","year":"2023","unstructured":"Song Y, Yoon DH, Yang H, et al. Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas. Ann Oncol. 2023;34(11):1055\u201363.","journal-title":"Ann Oncol"},{"key":"2089_CR8","volume-title":"Golidocitinib: Chinese prescribing information","author":"Dizal (Jiangsu) Pharmaceutical Co Ltd","year":"2024","unstructured":"Dizal (Jiangsu) Pharmaceutical Co Ltd. Golidocitinib: Chinese prescribing information. Shanghai: Dizal (Jiangsu) Pharmaceutical Co Ltd; 2024."},{"key":"2089_CR9","unstructured":"Dizal (Jiangsu) Pharmaceutical Co Ltd. Pipeline and strategy. 2023. https:\/\/dizalpharma.com\/innovation\/P&S. Accessed 12 Aug 2024."},{"key":"2089_CR10","unstructured":"Dizal (Jiangsu) Pharmaceutical Co Ltd. Golidocitinib approved in China as first-in-class JAK1 only inhibitor for the treatment of relapsed or refractory peripheral T-cell lymphoma [media release]. 19 June 2024. https:\/\/www.dizalpharma.com\/."},{"key":"2089_CR11","unstructured":"AstraZeneca. AstraZeneca and Chinese Future Industry Investment Fund establish joint venture to develop new medicines in China [media release]. 27 Nov 2017. https:\/\/www.astrazeneca.com."},{"issue":"S2","key":"2089_CR12","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/hon.3164_418","volume":"41","author":"Y Ye","year":"2023","unstructured":"Ye Y, Wu M, Mi L, et al. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Janus kinase 1 (JAK1) inhibitor AZD4205 on Peripheral T cell lymphoma [abstract no. 418]. Hematol Oncol. 2023;41(S2):558\u20139.","journal-title":"Hematol Oncol"},{"key":"2089_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1127935","author":"K Chen","year":"2023","unstructured":"Chen K, Guan X, Yang Z, et al. Pharmacokinetic characteristics of golidocitinib, a highly selective JAK1 inhibitor, in healthy adult participants. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1127935.","journal-title":"Front Immunol"},{"issue":"1","key":"2089_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1470-2045(23)00589-2","volume":"25","author":"Y Song","year":"2024","unstructured":"Song Y, Malpica L, Cai Q, et al. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study. Lancet Oncol. 2024;25(1):117\u201325.","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"2089_CR15","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1182\/blood-2023-185543","volume":"142","author":"J Jin","year":"2023","unstructured":"Jin J, Cai QQ, Zhang LL, et al. Phase 2 study of golidocitinib, a JAK1 selective inhibitor, as maintenance therapy in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26) [abstract no. 4430 plus poster]. Blood. 2023;142(Suppl 1):4430\u20132.","journal-title":"Blood"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02089-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02089-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02089-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T11:06:53Z","timestamp":1729940813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02089-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2089"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02089-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"28 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}